

Urinary Sodium and Potassium, and Risk of Ischaemic and Haemorrhagic Stroke (INTERSTROKE): a case-control study.

Dr Conor Judge MB a

Prof Martin J O'Donnell MB PhD a,b

Prof Graeme J. Hankey MD i

Sumathy Rangarajan MSc b

Siu Lim Chin b

Purnima Rao-Melacini MSc b

Dr John Ferguson PhD a

Dr Andrew Smyth PhD a

Prof Denis Xavier MD c

Prof Liu Lisheng MD d

Prof Hongye Zhang MD e

Prof Patricio Lopez-Jaramillo MD PhD f

Albertino Damasceno MD PhD g

Prof Peter Langhorne MB PhD h

Prof Annika Rosengren PhD b,f

Prof Antonio L Dans MD j

© The Author(s) 2020. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Prof Ahmed Elsayed MD k

Prof Alvaro Avezum MD l

Prof Charles Mondo MD PhD m

Prof Danuta Ryglewicz MD o

Prof Anna Czlonkowska MD PhD o

Prof Nana Pogossova MD p

Prof Christian Weimar MD n

Prof Rafael Diaz MD r

Prof Khalid Yusoff FRCP s

Prof Afzalhussein Yusufali MD t

Prof Aytekin Oguz MD u

Prof Xingyu Wang PhD e

Prof Fernando Lanas MD w

Okechukwu S Ogah MD x

Prof Adesola Ogunniyi MD y

Prof Helle K. Iversen z

Prof German Malaga MD aa

Prof Zvonko Rumboldt MD ab

Prof Shahram Oveisgharan MD ac

Prof Fawaz Al Hussain ae

Prof Salim Yusuf MB DPhil b

on behalf of the INTERSTROKE investigators.

^a NUI Galway, Galway, Ireland.

^b Population Health Research Institute, McMaster University and Hamilton Health Sciences,
Hamilton, ON, Canada.

^c St John's Medical College and Research Institute, Bangalore, India.

^d National Center of Cardiovascular Disease, Beijing, China.

^e Beijing Hypertension League Institute, Beijing, China.

^f Fundacion Oftalmologica de Santander-Clinica Carlos Ardila Lulle (FOSCAL), Bucaramanga,
Colombia.

^g Eduardo Mondlane University, Maputo, Mozambique.

^h Glasgow Royal Infirmary, University of Glasgow, Glasgow, Scotland, UK.

ⁱ School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia.

^j College of Medicine, University of Philippines, Manila, Philippines.

^k Al Shaab Teaching Hospital, Khartoum, Sudan.

^l Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil.

^m Uganda Heart Institute, Mulago Hospital, Kampala, Uganda.

ⁿ Department of Neurology, University Hospital, Essen, Germany.

^o Institute of Psychiatry and Neurology, Warsaw, Poland.

^p National Research Center for Preventive Medicine of the Ministry of Healthcare of the Russian Federation, Moscow, Russia.

^r Estudios Clinicos Latinoamerica, Rosario, Argentina.

^s UCSI University, Cheras, Kuala Lumpur, Malaysia.

^t Hatta Hospital, Dubai Health Authority/Dubai Medical College, Dubai, UAE.

^u İstanbul Medeniyet Üniversitesi, İstanbul, Turkey.

^w Faculty of Medicine, Universidad de La Frontera, Temuco, Chile.

^x Division of Cardiovascular Medicine, Department of Medicine, University College Hospital, Ibadan PMB 5116, Nigeria.

^y Department of Medicine, University College Hospital, PMB 5116, Ibadan, Nigeria.

^z Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

^{aa} Universidad Peruana Cayetano Heredia, Lima.

^{ab} University of Split, Croatia.

^{ac} Rush Alzheimer Disease Research Center in Chicago.

^{ae} Sahlgrenska Academy and University Hospital, University of Gothenburg, Gothenburg, Sweden

^{ag} King Saud University, Riyadh, Saudi Arabia.

Name and address of corresponding author

Dr Conor Judge, Health Research Board Clinical Research Facility, National University of Ireland,
Galway, Ireland conor.judge@nuigalway.ie

Conflict of interest statement

All authors declare: no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work.

Accepted Manuscript

Abstract

Background

Although low sodium intake (<2g/day) and high potassium intake (>3.5g/day) are proposed as public health interventions to reduce stroke risk, there is uncertainty about the benefit and feasibility of this combined recommendation on prevention of stroke and its subtypes.

Methods

We obtained random urine samples from 9,275 cases of acute first stroke and 9,726 matched controls (8,761 matched pairs for conditional analysis) from 27 countries and estimated the 24-hour sodium and potassium excretion, a surrogate for intake, using the Tanaka formula. Using multivariable conditional logistic regression, we determined the associations of estimated 24-hour urinary sodium and potassium excretion with stroke and its subtypes.

Results

The mean estimated 24-hour sodium and potassium urinary excretion was 3.29g/day and 1.57g/day, with 0.01% of participants having both low sodium (<2.0g/day) and high potassium excretion (>3.5g/day). There was a moderate positive correlation between sodium and potassium excretion ($r=0.4435$, $P<0.001$) and between sodium excretion and blood pressure ($P<0.001$). Compared with an estimated urinary sodium excretion of 2.8-3.5g/day (second quartile, reference), higher (>4.26g/day) (OR 1.81;95%CI,1.65-2.00) and lower (<2.8g/day) sodium excretion (OR 1.39;95%CI,1.26-1.53) were significantly associated with increased risk of stroke. The stroke risk associated with the highest quartile of sodium intake (sodium excretion >4.26g/day) was significantly greater ($P<0.001$) for intracerebral haemorrhage (ICH) (OR 2.38;95%CI,1.93-2.92) than for ischemic stroke (OR 1.67;95%CI,1.50-1.87), and greater for large vessel and small vessel ischemic stroke than for cardioembolic ischemic stroke. Urinary potassium was inversely and linearly associated with risk of stroke, and stronger for ischemic stroke than ICH ($P=0.026$). In an analysis of combined sodium and

potassium excretion, the combination of high potassium intake (>1.58g/day) and moderate sodium intake (2.8-3.5 g/day) was associated with the lowest risk of stroke.

Conclusion

The association of sodium intake and stroke is J-shaped, with high sodium intake a stronger risk factor for intracerebral haemorrhage than ischemic stroke. Our data suggest that moderate sodium intake – rather than low sodium intake – combined with high potassium intake may be associated with the lowest risk of stroke and expected to be a more feasible combined dietary target.

Keywords

Stroke, Ischaemic Stroke, Intracerebral haemorrhage, Sodium, Potassium

Accepted Manuscript

Introduction

Hypertension is the key modifiable risk factor for stroke and increasing sodium intake is positively associated with blood pressure.[1,2] Reduction of sodium intake, to low intake levels of 2g/day or lower, has been proposed to be an effective population-level intervention to reduce blood pressure, and inferentially, reduce the burden of stroke.[3–5] However, despite the modest positive association between sodium intake and blood pressure,[6] the pattern of association of sodium intake with cardiovascular disease is consistently J-shaped in a number of large epidemiologic studies, [7–9] despite using different methods to estimate sodium intake (24-hour urine collection, early morning fasting samples, or random non-fasting urine samples). For stroke, individual studies report an inconsistent relationship between sodium intake and stroke, with different epidemiologic studies reporting a linear association, a curvilinear relationship, or J-shaped association.[10] In addition, the association of high sodium intake with stroke persists in most observational studies, after adjusting for blood pressure, suggesting mechanisms other than blood pressure may also mediate the increased cardiovascular risk.[7]

Considerable public health efforts and resources are being invested in targeting low sodium intake (<2 g/day) [11], although there is controversy about whether low sodium intake represents the optimal target for cardiovascular prevention. Moreover, the feasibility of a combined target of low sodium and high potassium intake is challenged because only a very small proportion of the population consume this joint electrolyte target;[12,13] sodium and potassium intake usually correlate positively with each other indicating that targeting low sodium intake is more likely to be associated with reductions in potassium intake among free-living individuals, and vice-versa.[14] Increased potassium intake appears to be an important target for stroke prevention, with meta-analyses reporting a linear reduction in stroke risk associated with increased potassium intake.[15] Studies also suggest that the adverse cardiovascular effects of high sodium intake may be mitigated with high potassium intake.[12,16,17] Therefore, evaluating the association of sodium intake with

stroke necessarily requires a combined analysis of the relationship of both electrolytes with stroke risk overall, and within stroke subtypes.[17]

INTERSTROKE was a standardised international case-control study that included participants from 30 countries.[1] The unique aspects of this observational study are the breadth of the international population included, the standardised measurement of vascular risk factors (including diet) and the valid determination of primary stroke subtype (ischemic or intracerebral haemorrhage) using neuroimaging.

In this paper, we report the individual, and joint, associations of estimated sodium and potassium excretion (surrogates for intake) with stroke and its subtypes.

Methods

Study design and participants

INTERSTROKE is a large, international case control study of risk factors for first stroke. 13,462 stroke patients and 13,483 matched controls were recruited between Jan 11, 2007 and Aug 8, 2015. For the current analyses, we include 9,275 cases and 9,726 controls with urinary measures of sodium and potassium (8,761 matched pairs for conditional analysis). Each case was matched for sex and age (± 5 years) with controls (Supplementary Table 1). Cases were patients with first acute stroke, either ischaemic or intracerebral haemorrhage, with confirmation by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) brain imaging. Patients with stroke were enrolled within five days of symptom onset and within 72 hours of hospital admission. Stroke severity was measured using the modified Rankin Scale at the time of recruitment and at 1-month follow-up. The study was approved by the ethics committees in all participating centres. Written informed consent was obtained from participants or their proxy.

Measurement of Risk Factors

Standardized questionnaires were used to collect data on demographics, lifestyle stroke risk factors and characteristics of acute stroke from all cases and controls (Supplementary Table 2). Physical measurements of weight, height, waist and hip circumferences, heart rate, blood pressure were recorded in a standardised manner. In cases, blood pressure and heart rate were measured at three time-points: at admission, the next morning and at the time of interview. A modified-Rankin scale score was collected at three time-points for cases: pre-admission, time of interview and at one-month follow-up (either in person or by phone) and one time-point for controls (time of interview). Ischemic stroke subtype was based on clinical assessment (baseline and one-month), neuroimaging (baseline) and results of tests to determine aetiology (ultrasound of carotids, cardiac imaging and cardiac monitoring). Hypertension was defined as a composite of self-reported hypertension and a blood pressure reading of greater than 140/90 mmHg at recruitment. Diabetes mellitus was defined as self-reported diabetes or a HbA1c of greater than 6.5% at recruitment.

Blood and Urine collection and analysis

Non-fasting blood and urine samples were taken from cases within 72 hours of recruitment and controls (at the time of interview), frozen at -20° to -70° and shipped to core laboratories (Hamilton-Canada, Beijing-China, Bangalore-India and Istanbul-Turkey). Several formulae exist for estimation of 24-hr sodium and potassium excretion from spot urinary sodium/potassium measurements.[18–20] These formulae have been validated against 24-hr urine collections [21] and serve as a valid measure of mean population sodium and potassium intake.[22] The Tanaka formula was used to estimate 24-hour urine sodium and potassium excretion [18] and is reported to be associated with the least biased estimate for casual (non-fasting) urine samples in an international population.[21]

Statistical analysis

We calculated the correlation between urinary sodium and potassium excretion using Pearson's correlation coefficient, and of sodium and potassium excretion with blood pressure using an intra-class correlation coefficient (ICC) in controls (excluding those with known hypertension or taking diuretics). We used multivariable conditional logistic regression to evaluate the association of sodium and potassium excretion with stroke, employing restricted cubic-spline plots to explore the pattern of association.[23] For analysis of categories of estimated sodium excretion, we set the reference group as the second quartile (2.8-3.5g/day), as this was identified as the lowest risk category on initial univariate analyses, and consistent with the range of lowest risk on cubic splines. Similarly, we set the first quartile (<1.34 g/day) as the reference group for estimated potassium excretion.

We adjusted for covariates in four sequential models. Model 1 was adjusted for age and body mass index (BMI). Model 2 (the primary model) was additionally adjusted for education level (none-reference, 1-8 years, 9-12 years, Trade School, College/University), alcohol intake (never-reference, former, current), diabetes, atrial fibrillation or flutter, smoking (never-reference, former, current) and physical activity level (strenuous-reference, moderate, mild, mainly sedentary). Model 3 included all the variables in model 2 and added, estimated excretion of potassium (Tanaka) and the alternative healthy eating index (AHEI) dietary score as an overall measure of diet quality. Model 4 included hypertension status, mean systolic blood pressure, mean diastolic blood pressure and medications which modify sodium excretion, which was a model to explore variables potentially along the causal pathway mediating the association of sodium and potassium intake with stroke. Model 4 was reproduced separately with the three components of the mean blood pressure variable; time of admission, the morning after admission and during the interview. We examined the consistency of these associations by performing analyses in subgroups using our primary model (conditional analysis) based on key characteristics that might modify the association between sodium, potassium, and stroke (ethnicity, body mass index (BMI), sex, age, hypertension, and

diuretic therapy), using the Wald test to assess statistical interactions. We excluded small subgroups (<500 participants).

We performed an analysis of the combined effects of sodium and potassium excretion, in which we generated eight categories (4X2) by sodium excretion quartile (<2.8 g/day, 2.8-3.5 g/day, 3.5-4.26 g/day and >4.26 g/) and potassium excretion above and below median (1.58 g/day). We completed a sensitivity analysis in which we excluded patients (cases) with a modified Rankin score greater than 2, as such patients may more likely not consume their usual diets and may receive co-interventions (e.g. intravenous fluids and enteric feeding due to their disability). Given that time from hospital admission to sample collection may also affect the classification of intake categories, we completed an analysis that excluded participants with samples collected greater than 48 hours after admission. All analyses were performed using R version 3.5.3 (Great Truth).

Role of the funding source

The study funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Results

INTERSTROKE participants

Between Jan 11, 2007 and Aug 8, 2015, the INTERSTROKE study enrolled 9,275 cases of acute first stroke and 9,726 matched controls (8,761 matched pairs for conditional analysis) who also had urinary samples collected. Table 1 and Supplementary Table 3 (sodium) and Supplementary Table 4 (potassium) outline the characteristics of patients including co-morbidities, stroke type, stroke severity and blood pressure by quartiles of sodium and potassium excretion. The mean time between stroke onset and collection of urine sample was 2.08 ± 1.27 days and the mean time between hospitalisation and collection of urine sample was 1.51 ± 1.04 days. Figure 1 reports the scatterplot and a statistically significant correlation ($R=0.4435$, $p<0.0001$) between estimated urinary sodium and potassium excretion for cases and controls in the INTERSTROKE population. The mean

24-hour sodium excretion per day was 3.69g for cases and 3.54g for control ($P<0.001$) (Table 1). The mean 24-hour potassium excretion per day were 1.57g for cases and 1.68g for controls ($P<0.001$) (Supplementary Table 4).

Estimated sodium excretion (quartiles) and blood pressure

Figure 2 reports the association of urinary sodium excretion and blood pressure among controls not receiving antihypertensive therapy or diuretics and indicates a graded increase in blood pressure with increasing sodium intake. For each 1-g increment in estimated sodium excretion, there was an increment of 1.01 mmHg in systolic blood pressure ($P<0.001$) and an increment of 0.48 mmHg in diastolic blood pressure ($P<0.001$).

Estimated sodium excretion (quartiles) and risk of stroke and stroke subtypes

Compared to Q2 (sodium excretion of 2.8-3.5g/day [reference]), Q1 (OR 1.39;95%CI,1.26-1.53, sodium excretion <2.8 g/day) and Q4 (OR 1.81;95%CI,1.65-2.00, sodium excretion >4.26 g/day) were associated with significant increases in the risk of all stroke. The highest quartile (Q4 >4.26 g/day) was more strongly associated with ICH (OR 2.38;95%CI,1.93-2.92) than ischemic stroke (OR 1.67;95%CI,1.50-1.87) ($P<0.001$). Sodium excretion <2.8 g/day was significantly associated with both ischemic stroke (OR 1.36;95%CI,1.22-1.52) and ICH (OR 1.62;95%CI,1.32-1.99) (Figure 3 and Supplementary Tables 5-6). The association of high sodium excretion (>4.26 g/day) and stroke remained significant after adjustment for blood pressure and prior history of hypertension (OR 2.35;95%CI,2.08-2.65). Within ischemic stroke subtypes, the association of high sodium intake was significant for small vessel and large vessel ischemic stroke, but not significant for cardioembolic stroke (Figure 4).

Estimated potassium excretion and risk of stroke and stroke subtypes

Compared to Q1 (potassium excretion of <1.34g/day [reference]), Q2 (OR 0.83;95%CI,0.76-0.92, potassium excretion 1.34-1.58g/day), Q3 (OR 0.68;95%CI,0.62-0.75, potassium excretion 1.58-1.86g/day), and Q4 (OR 0.46;95%CI,0.41-0.51, potassium excretion >1.86g/day) were all associated with a significant lower risk of all stroke, which was largely related to the association of potassium excretion with ischemic stroke and there was no significant association with ICH (Figure 5).

Joint Urinary Sodium and Potassium excretion and risk of stroke

For all stroke, compared with a joint reference category of moderate sodium excretion (2.8-3.5 g/day) and high potassium intake (≥ 1.58 g/day)(lowest risk category), all other categories were associated with an increased risk of stroke, with sodium excretion >4.26g/day and potassium excretion <1.58g/day reporting the highest magnitude of risk (OR 4.17;95%CI,3.51-4.96) (Table 4, Supplementary Figures 1-2). The magnitude of association is reduced for both low (<2.8g/day) and high (>4.26g/day) sodium excretion when potassium excretion is high (≥ 1.58 g/day)($P < 0.001$ for interaction)(Table 4).

Subgroup and sensitivity analysis of the associations between sodium and potassium excretion and risk of stroke

There was a significantly increased risk of stroke for Q4 (>4.26g/day) versus Q2 (2.8-3.5 g/day) in participants with a BMI less than or equal to 30 (OR 1.92,95%CI,1.72-2.15) compared to participants with a BMI greater than 30 (OR 1.35,95% CI,0.81-2.26) ($P = 0.009$ for interaction). The association of high sodium excretion with stroke (>4.26g/day) versus Q2 (2.8-3.5 g/day) was significant for European (OR 1.34,95%CI,1.11-1.63), Chinese (OR 1.85, 95% CI, 1.59-2.14), Other Asian (OR 10.83 (6.35-18.48), Latin American (OR 1.61,95%CI,1.23-2.13), Black African (OR 1.95,95%CI,1.10-3.47), and "Other" African ethnicity (OR 1.96,95%CI,1.12-3.43). The association of low sodium excretion with stroke (<2.8g/day) versus Q2 (2.8-3.5 g/day) was significant for European (OR 1.57,95%CI,1.30-1.89), Arab (OR 2.51,95%CI,1.13-5.56), Latin American (OR 1.40,95%CI,1.06-1.87), Black African (OR

2.21,95%CI,1.37-3.55), and Other ethnicity (OR 2.21,95%CI,1.43-3.41)($P<0.001$ for interaction). The associations for both high sodium excretion (OR 1.46,95%CI,0.77-2.76) and low sodium excretion (OR 1.55,95%CI,0.71-3.41) compared to Q2 (2.8-3.5 g/day) were non-significant for participants with diuretic use at baseline ($P=0.1505$ for interaction). Sex, age or baseline hypertension status did not alter the association significantly between both high and low estimated sodium excretion and stroke (Supplementary Table 7).

The exclusion of cases with modified Rankin scale greater than two, and the exclusion of cases with urine collected greater than forty-eight hours after symptom onset did not materially alter findings (Table 2 and 3).

We repeated all analyses with the Kawasaki formula, urinary sodium/creatinine ratio and urinary sodium, which revealed consistent patterns of association, but, as expected, different thresholds of sodium and potassium excretion (grams per day) were associated with stroke risk (Supplementary Figure 3-6).

Conclusions

In this large, international, case-control study, we report an overall J-shaped association between sodium intake and stroke risk, with the lowest risk at moderate sodium intake (2.8-3.5g/day), employing estimated 24-hour urinary excretion of sodium as a surrogate for intake. The association of high sodium intake was stronger for intracerebral haemorrhage compared to ischaemic stroke and within ischemic stroke subtypes, was significant for small vessel and large vessel ischemic stroke, but not significant for cardioembolic stroke. The association between estimated potassium excretion and risk of ischemic stroke was inverse and linear, but not significant for ICH. The magnitude of association for both low (<2.8 g/day) and high (>4.26 g/day) sodium excretion was diminished in those with high potassium intake (≥ 1.58 g/day) ($P<0.001$ for interaction). In our analysis of combined categories of sodium and potassium intake, the category of highest potassium

intake (≥ 1.58 g/day) and moderate sodium intake (2.8-3.5 g/day) was associated with the lowest risk of stroke.

Most national and international guidelines recommend low sodium intake in the entire population, for stroke prevention (e.g. WHO recommend an intake of < 2.0 g/day by WHO). Primarily, the target of low sodium is based on the short-term Phase IIa DASH-Sodium trial which reported a blood pressure reduction when reducing sodium intake to less than 1.5g/day by providing all meals to the participants,[24] the longer-term trials (TONE and TOHP-2) which achieved mean sodium intakes of 2.3g/day and 3.11g/day (despite targeting a sodium intake of 1.8g/day or lower) through intense dietary counselling.[25,26] While a target of < 2.0 g/day can be achieved in a highly controlled environment, we report that a very low proportion of the population consume a low sodium intake, and an even lower proportion consume a combined low sodium and high potassium intake. Our findings are consistent with other epidemiologic studies, and support the contention that a lower limit of sodium intake exists among free living populations due to neurohormonal control mechanisms that auto regulate the consumption of sodium.[27] Activation of the renin-angiotensin-aldosterone system occurs when sodium intake falls below approximately 3.0 g per day. An analysis of the HOPE study reported a positive association between higher quintiles of plasma renin activity and cardiovascular outcomes including stroke [28], and consistently, the relative risk for the highest quintile of plasma renin activity was 1.43, identical to our estimate for the stroke risk associated with sodium excretion < 2.8 g/day. In addition, we report a different pattern of association between sodium intake and blood pressure (positive and monotonic) compared to the pattern of association with stroke risk (J-shaped). These patterns have also been reported in several recent large cohort studies,[7,29] and challenge assumptions that underpin current guidelines (i.e. that all reductions in blood pressure will reduce stroke, regardless of baseline sodium intake level).[9] Our findings do however, support public health interventions to reduce sodium intake among populations with high sodium intake and support transitioning populations from high to moderate

sodium intake in order to reduce stroke.[30] Our data suggest that the risk associated with a higher sodium intake may be greater in regions outside of Europe and North America.

Our data also provide important insights into the anticipated effects of reducing high sodium intake on patterns of stroke and its subtypes; reducing high sodium intake is likely to have a greater effect on reducing ICH than ischaemic stroke, but is nevertheless expected to also reduce ischaemic stroke, and thereby the global burden of all stroke. In ecological studies of stroke incidence in China, for example, population-level reductions in high sodium intake parallel reductions in stroke incidence, and are more marked for ICH than ischemic stroke.[31] In the INTERSTROKE study, about 40% of the control population were consuming higher sodium intake in a range associated with stroke risk, supporting a targeted-population approach to sodium reduction, rather than a population-wide approach.

Our analyses also suggest that increases in potassium intake may be of comparable, or greater, importance to stroke prevention than reductions in sodium intake. [12,16,17] This finding is consistent with reports that high potassium intake is a marker of a healthy diet i.e. rich in fruit and vegetables.[32]

A recent analysis of the PURE cohort study reported that the combination of moderate sodium intake and high potassium intake was associated with the lowest cardiovascular risk, and our analyses are further evidence that such a combined target may be optimal.[12] A cluster randomised controlled trial reported significant reductions in cardiovascular risk with potassium salt substitution.[33] Potassium salt substitution not only increased potassium intake but also reduced high sodium intake (but not to low intake levels).[33] An ongoing large cluster randomized controlled trial in China is currently evaluating potassium salt substitutes for prevention of stroke.[34] Our analyses, and those of other studies, raise major concerns about the feasibility of increasing potassium intake, while simultaneously achieving low sodium intake. They suggest that populations

should target moderate sodium intake and high potassium intake as the optimal balance, as the former is expected to make the latter more achievable.

Measurement of sodium and potassium intake is a major challenge, and there is no “gold” standard for estimating usual sodium and potassium intake.[35] The reference standard,[36] repeated 24-hour urinary collections, is impractical in large epidemiologic studies and would invariably lead to the exclusion of a substantial proportion of participants and a biased sample. In our study, the mean intake of sodium in the control group was 3.54g/day, which is close to the mean intake reported by the Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (3.95g/day) and the PURE study (4.9g/day).[7,37] In the PURE study, a fasting morning urine sample was collected and the Kawasaki formula was used to estimate sodium excretion. In contrast, we collected a random urine sample and used the Tanaka formula to estimate sodium excretion. A validation study of 1083 participants from the PURE study showed a similar differences between mean sodium estimated using the Kawasaki equation and Tanaka equation.[21]. Importantly, however, irrespective of the method we employed in INTERSTROKE, which included urinary sodium/creatinine ratio, Tanaka formula or Kawasaki formula, the J-shaped pattern of association were consistent among all analyses, and median intake levels are associated with lowest cardiovascular risk. Collectively, despite the study-by-study variation in methods of estimating sodium intake, there is a remarkable consistency in findings from large epidemiologic studies that the optimal range of sodium intake resides within a range between 2.7-5.0g/day. This is also the range identified in a meta-analysis of prospective cohort studies published before 2014 [9], by Graudal et al, and consistent with prospective cohort studies reported since then, including PURE [12], CRIC [38] and PREVEND [39] studies.

The case control design has inherent limitations, including sampling bias (selection of cases and controls) and measurement bias (recall bias). Sensitivity analysis by control type (community versus hospital) did not alter our findings and estimated urinary sodium excretion is an objective lab

measurement and not susceptible to recall bias. Another limitation is the potential acute effects of stroke on excretion of sodium intake, particularly the change in oral intake and use of intravenous fluids in those with severe stroke. To address this issue, we performed several sensitivity analyses by excluding patients with a modified Rankin score greater than two as these patients are likely have received intravenous fluids and enteric feeding due to their disability. Excluding these patients did not materially alter our findings. In addition, increasing time from admission to urinary sample measurement may reduce the correlation of usual (pre-stroke) diet with urinary estimate. Confining the analyses to those with early urine collections did not alter conclusions.

A key strength of the INTERSTROKE study was the availability of neuroimaging to classify all cases of stroke. INTERSTROKE is the only large study which reliably examines whether the associations of sodium and potassium differs between ischaemic stroke, ischaemic stroke subtypes and ICH. Obtaining such information from cohort studies is impractical. The diverse international population included in our results are widely generalizable.

In conclusion, an estimated sodium excretion $<2.8\text{g/day}$ and $>4.26\text{g/day}$ are both associated with an increased risk of stroke (reference $2.8\text{--}3.5\text{g/day}$). An estimated potassium excretion of greater than 1.34g/day were both associated with a reduced risk of stroke (reference $<1.34\text{g/day}$). In the absence of large randomised controlled trials, the collective information from observational data on over 300,000 individuals suggests that the optimal intake of sodium is a moderate level combined with high potassium intake.

Authors' contributions

MJO'D and SY designed the study. CJ and MJO'D planned analyses and wrote the first draft of the report. CJ and JF did the statistical analyses. All authors contributed to the collection of data, discussions and interpretation of the data, and to the writing of the report. All authors had full access to data and reviewed and approved the drafts of the report

Conflict of interest statements

GJH reports personal fees from Bayer and Medscape, outside of the submitted work. All other authors declare no competing interests.

Role of funding source

The INTERSTROKE study is funded by the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, Swedish Research Council, Swedish Heart and Lung Foundation, The Health & Medical Care Committee of the Regional Executive Board, Region Västra Götaland, and through unrestricted grants from several pharmaceutical companies with major contributions from Astra Zeneca, Boehringer Ingelheim (Canada), Pfizer (Canada), MERCK, Sharp and Dohme], Swedish Heart and Lung Foundation, UK Chest, and UK Heart and Stroke. The sponsors had no role in data collection, analyses or the decision to submit for publications.

Ethics committee approval

The study was approved by the ethics committees in all participating centres.

References

1. O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, McQueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener H-C, Ryglewicz D, Czlonkowska A, Pogossova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Penaherrera E, Lanan F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Al Hussain F, Magazi D, Nilanont Y, Ferguson J, Pare G, Yusuf S. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *The Lancet*. 2016 Aug;388(10046):761–75.
2. Mente A, O'Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, Morrison H, Li W, Wang X, Di C, Mony P, Devanath A, Rosengren A, Oguz A, Zatonska K, Yusufali AH, Lopez-Jaramillo P, Avezum A, Ismail N, Lanan F, Puoane T, Diaz R, Kelishadi R, Iqbal R, Yusuf R, Chifamba J, Khatib R, Teo K, Yusuf S. Association of Urinary Sodium and Potassium Excretion with Blood Pressure. *N Engl J Med*. 2014 Aug 14;371(7):601–11.
3. World Health Organization (WHO). Guideline: Sodium intake for adults and children. [Internet]. Geneva; 2012 [cited 2018 Nov 19]. Available from: http://www.who.int/nutrition/publications/guidelines/sodium_intake_printversion.pdf
4. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD, American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. *Circulation*. 2010 Feb 2;121(4):586–613.
5. Cao J, Eshak ES, Liu K, Gero K, Liu Z, Yu C. Age-Period-Cohort Analysis of Stroke Mortality Attributable to High Sodium Intake in China and Japan. *Stroke*. 2019 Jul;50(7):1648–54.
6. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. *Cochrane Database Syst Rev*. 2013 Apr 30;(4):CD004937.
7. O'Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee SF, Mony P, Devanath A, Rosengren A, Lopez-Jaramillo P, Diaz R, Avezum A, Lanan F, Yusoff K, Iqbal R, Ilow R, Mohammadifard N, Gulec S, Yusufali AH, Kruger L, Yusuf R, Chifamba J, Kabali C, Dagenais G, Lear SA, Teo K, Yusuf S. Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events. *N Engl J Med*. 2014 Aug 14;371(7):612–23.
8. Cogswell ME, Mugavero K, Bowman BA, Frieden TR. Dietary Sodium and Cardiovascular Disease Risk — Measurement Matters. *N Engl J Med*. 2016 Aug 11;375(6):580–6.
9. Graudal N, Jürgens G, Baslund B, Alderman MH. Compared With Usual Sodium Intake, Low- and Excessive-Sodium Diets Are Associated With Increased Mortality: A Meta-Analysis. *Am J Hypertens*. 2014 Sep 1;27(9):1129–37.
10. Zhu Y, Zhang J, Li Z, Liu Y, Fan X, Zhang Y, Zhang Y. Association of sodium intake and major cardiovascular outcomes: a dose-response meta-analysis of prospective cohort studies. *BMC Cardiovasc Disord* [Internet]. 2018 Oct 19 [cited 2019 Sep 21];18. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194706/>

11. Collins M, Mason H, O'Flaherty M, Guzman-Castillo M, Critchley J, Capewell S. An Economic Evaluation of Salt Reduction Policies to Reduce Coronary Heart Disease in England: A Policy Modeling Study. *Value Health*. 2014 Jul;17(5):517–24.
12. O'Donnell M, Mente A, Rangarajan S, McQueen MJ, O'Leary N, Yin L, Liu X, Swaminathan S, Khatib R, Rosengren A, Ferguson J, Smyth A, Lopez-Jaramillo P, Diaz R, Avezum A, Lanas F, Ismail N, Yusoff K, Dans A, Iqbal R, Szuba A, Mohammadifard N, Oguz A, Yusufali AH, Alhabib KF, Kruger IM, Yusuf R, Chifamba J, Yeates K, Dagenais G, Wielgosz A, Lear SA, Teo K, Yusuf S, the PURE Investigators. Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. *BMJ*. 2019 Mar 13;1772.
13. Drewnowski A, Rehm CD, Maillot M, Mendoza A, Monsivais P. The feasibility of meeting the WHO guidelines for sodium and potassium: a cross-national comparison study. *BMJ Open*. 2015 Mar 20;5(3):e006625–e006625.
14. Yang Q. Sodium and Potassium Intake and Mortality Among US Adults: Prospective Data From the Third National Health and Nutrition Examination Survey. *Arch Intern Med*. 2011 Jul 11;171(13):1183.
15. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. *BMJ*. 2013 Apr 3;346(apr03 3):f1378–f1378.
16. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin P-H, Karanja N, Simons-Morton D, McCullough M, Swain J, Steele P, Evans MA, Miller ER, Harsha DW. A Clinical Trial of the Effects of Dietary Patterns on Blood Pressure. *N Engl J Med*. 1997 Apr 17;336(16):1117–24.
17. Cook NR. Joint Effects of Sodium and Potassium Intake on Subsequent Cardiovascular Disease: The Trials of Hypertension Prevention Follow-up Study. *Arch Intern Med*. 2009 Jan 12;169(1):32.
18. Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, Hashimoto T. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. *J Hum Hypertens*. 2002 Feb;16(2):97–103.
19. Kawasaki T, Itoh K, Uezono K, Sasaki H. A simple method for estimating 24 h urinary sodium and potassium excretion from second morning voiding urine specimen in adults. *Clin Exp Pharmacol Physiol*. 1993 Jan;20(1):7–14.
20. Brown IJ, Dyer AR, Chan Q, Cogswell ME, Ueshima H, Stamler J, Elliott P. Estimating 24-Hour Urinary Sodium Excretion From Casual Urinary Sodium Concentrations in Western Populations. *Am J Epidemiol*. 2013 Jun 1;177(11):1180–92.
21. Mente A, O'Donnell MJ, Dagenais G, Wielgosz A, Lear SA, McQueen MJ, Jiang Y, Xingyu W, Jian Bo, Calik KBT, Akalin AA, Mony P, Devanath A, Yusufali AH, Lopez-Jaramillo P, Avezum A, Yusoff K, Rosengren A, Kruger L, Orlandini A, Rangarajan S, Teo K, Yusuf S. Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries: *J Hypertens*. 2014 May;32(5):1005–15.
22. O'Brien E. Salt—too much or too little? *The Lancet*. 2016 Jul;388(10043):439–40.

23. Harrell FE. Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. Second edition. Cham Heidelberg New York: Springer; 2015. 582 p. (Springer series in statistics).
24. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, Simons-Morton DG, Karanja N, Lin P-H, Aickin M, Most-Windhauser MM, Moore TJ, Proschan MA, Cutler JA. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. *N Engl J Med*. 2001 Jan 4;344(1):3–10.
25. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH, Kostis JB, Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*. 1998 Mar 18;279(11):839–46.
26. Effects of Weight Loss and Sodium Reduction Intervention on Blood Pressure and Hypertension Incidence in Overweight People With High-Normal Blood Pressure: The Trials of Hypertension Prevention, Phase II. *Arch Intern Med*. 1997 Mar 24;157(6):657.
27. Lowell BB. New Neuroscience of Homeostasis and Drives for Food, Water, and Salt. *N Engl J Med*. 2019 Jan 31;380(5):459–71.
28. Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. *Eur Heart J*. 2011 Sep;32(17):2135–42.
29. Stolarz-Skrzypek K. Fatal and Nonfatal Outcomes, Incidence of Hypertension, and Blood Pressure Changes in Relation to Urinary Sodium Excretion. *JAMA*. 2011 May 4;305(17):1777.
30. Hyseni L, Elliot-Green A, Lloyd-Williams F, Kypridemos C, O’Flaherty M, McGill R, Orton L, Bromley H, Cappuccio FP, Capewell S. Systematic review of dietary salt reduction policies: Evidence for an effectiveness hierarchy? Shankar B, editor. *PLOS ONE*. 2017 May 18;12(5):e0177535.
31. Li Y, Huang Z, Jin C, Xing A, Liu Y, Huangfu C, Lichtenstein AH, Tucker KL, Wu S, Gao X. Longitudinal Change of Perceived Salt Intake and Stroke Risk in a Chinese Population. *Stroke*. 2018 Jun;49(6):1332–9.
32. Mente A, Irvine EJ, Honey RJD, Logan AG. Urinary Potassium Is a Clinically Useful Test to Detect a Poor Quality Diet. *J Nutr*. 2009 Apr 1;139(4):743–9.
33. Chang H-Y, Hu Y-W, Yue C-SJ, Wen Y-W, Yeh W-T, Hsu L-S, Tsai S-Y, Pan W-H. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. *Am J Clin Nutr*. 2006 Jun 1;83(6):1289–96.
34. Neal B, Tian M, Li N, Elliott P, Yan LL, Labarthe DR, Huang L, Yin X, Hao Z, Stepien S, Shi J, Feng X, Zhang J, Zhang Y, Zhang R, Wu Y. Rationale, design, and baseline characteristics of the Salt Substitute and Stroke Study (SSaSS)—A large-scale cluster randomized controlled trial. *Am Heart J*. 2017 Jun;188:109–17.
35. Versi E. “Gold standard” is an appropriate term. *BMJ*. 1992 Jul 18;305(6846):187.

36. McLean R. Measuring Population Sodium Intake: A Review of Methods. *Nutrients*. 2014 Oct 28;6(11):4651–62.
37. Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, Lim S, Danaei G, Ezzati M, Powles J. Global Sodium Consumption and Death from Cardiovascular Causes. *N Engl J Med*. 2014 Aug 14;371(7):624–34.
38. Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane MG, Mohler E, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Steigerwalt S, Townsend R, He J. Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease. *JAMA*. 2016 May 24;315(20):2200–10.
39. Kieneker LM, Eisenga MF, Gansevoort RT, de Boer RA, Navis G, Dullaart RPF, Joosten MM, Bakker SJL. Association of Low Urinary Sodium Excretion With Increased Risk of Stroke. *Mayo Clin Proc*. 2018 Dec;93(12):1803–9.

Accepted Manuscript

Figure Legends

Figure 1 – Scatterplot of Estimated Urinary Sodium and Potassium Excretion

Figure 2 – Mean Systolic and Diastolic Blood Pressure by Sodium Quartile
(Controls excluding baseline hypertension and pre-hospital diuretic use)

Figure 3 – Association of estimated 24-hour sodium excretion (Tanaka) with risk of stroke and pathological stroke subtypes

Panel A shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and risk of all stroke. Panel B shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and risk of ischemic stroke. Panel C shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and risk of intracerebral haemorrhage. All plots were adjusted for age, BMI, education level, alcohol intake, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level. The grey ribbons indicate 95% confidence interval. The green lines represents the median value for each population. The distribution of the exposure (sodium excretion) is plotted below each spline.

Figure 4 – Association of estimated sodium excretion (Tanaka) and risk of ischaemic stroke subtypes (TOAST classification)

Panel A shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and cardioembolic stroke (TOAST 1). Panel B shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and large vessel stroke (TOAST 2). Panel C shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and small vessel stroke (TOAST 3). Panel D shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and stroke of undetermined cause (TOAST 4). All plots were adjusted for age, BMI, education level, alcohol intake, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level. The grey ribbons indicate 95% confidence interval. The distribution of the exposure (potassium excretion) is plotted below each spline.

Figure 5 – Association of estimated 24-hour potassium excretion (Tanaka) with risk of stroke and pathological stroke subtypes

Panel A shows a restricted cubic spline of the association between estimated 24-hour potassium excretion and risk of all stroke. Panel B shows a restricted cubic spline of the association between estimated 24-hour potassium excretion and risk of ischemic stroke. Panel C shows a restricted cubic spline of the association between estimated 24-hour potassium excretion and risk of intracerebral haemorrhage. All plots were adjusted for age, BMI, education level, alcohol intake, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level. The grey ribbons indicate 95% confidence interval. The green lines represents the median value for each population. The distribution of the exposure (sodium excretion) is plotted below each spline.

Tables

Table 1 – Characteristics of the Study Participants at Baseline, According to Estimated Sodium Excretion (Conditional Analysis)

Characteristic	Case					Control				
	All (N=8761)	<2.8 g/day (N=2214)	2.8-3.5 g/day (N=1911)	3.5-4.3 g/day (N=2065)	>4.3 g/day (N=2571)	All (N=8767)	<2.8 g/day (N=2075)	2.8-3.5 g/day (N=2481)	3.5-4.3 g/day (N=2352)	>4.3 g/day (N=1859)
Estimated excretion - g/day										
Sodium	3.69±1.28	2.23±0.44	3.19±0.20	3.88±0.21	5.18±1.02	3.54±1.04	2.32±0.41	3.19±0.20	3.88±0.21	4.93±0.93
Potassium	1.58±0.38	1.43±0.30	1.49±0.33	1.56±0.34	1.78±0.42	1.68±0.42	1.48±0.35	1.62±0.39	1.75±0.40	1.88±0.44
Age - yr	62.9±13.4	63.9±13.7	63.0±13.4	62.5±13.2	62.3±13.2	62.1±13.2	63.7±13.5	62.0±13.2	61.3±12.9	61.5±13.0
Female Sex - no. (%)	3574 (40.8)	959 (26.8)	770 (21.5)	797 (22.3)	1048 (29.3)	3580 (40.8)	925 (25.8)	978 (27.3)	929 (25.9)	748 (20.9)
Geographic region - no. (%)										
Western Europe / North America	1544 (17.6)	567 (36.7)	394 (25.5)	302 (19.6)	281 (18.2)	1544 (17.6)	381 (24.7)	439 (28.4)	447 (29.0)	277 (17.9)
Eastern / Central Europe / Middle East	1079 (12.3)	206 (19.1)	213 (19.7)	290 (26.9)	370 (34.3)	1079 (12.3)	211 (19.6)	287 (26.6)	322 (29.8)	259 (24.0)
Africa	587 (6.70)	278 (47.4)	126 (21.5)	90 (15.3)	93 (15.8)	587 (6.70)	213 (36.3)	192 (32.7)	118 (20.1)	64 (10.9)
China	3891 (44.4)	728 (18.7)	836 (21.5)	1053 (27.1)	1274 (32.7)	3891 (44.4)	832 (21.4)	1089 (28.0)	1051 (27.0)	919 (23.6)

South East											
Asia	615 (7.02)	155 (25.2)	123 (20.0)	125 (20.3)	212 (34.5)	615 (7.01)	204 (33.2)	214 (34.8)	126 (20.5)	71 (11.5)	
South America	1045 (11.9)	280 (26.8)	219 (21.0)	205 (19.6)	341 (32.6)	1051 (12.0)	234 (22.3)	260 (24.7)	288 (27.4)	269 (25.6)	
Stroke type - no. (%)											
Ischemic	6805 (77.7)	1710 (77.4)	1537 (81.0)	1646 (80.0)	1912 (74.7)	-	-	-	-	-	
ICH	1919 (21.9)	499 (22.6)	361 (19.0)	411 (20.0)	648 (25.3)	-	-	-	-	-	
Hypertension - no. (%)	5243 (59.8)	1363 (61.6)	1134 (59.3)	1192 (57.7)	1554 (60.4)	3299 (37.6)	974 (46.9)	998 (40.2)	988 (42.0)	856 (46.0)	
Blood pressure - mm Hg											
Systolic	148±21.2	149±22.0	147±20.8	148±20.5	149±21.3	133±18.5	133±19.1	133±18.3	133±17.8	134±18.7	
Diastolic	86.5±12.3	87.0±13.2	85.4±12.1	86.5±11.8	86.9±12.0	80.1±10.7	79.3±11.2	79.8±10.5	80.3±10.3	81.1±10.6	
Cholesterol - mmol/litre											
HDL	1.15±0.35	1.18±0.37	1.16±0.37	1.14±0.34	1.12±0.33	1.22±0.37	1.22±0.38	1.23±0.38	1.21±0.35	1.20±0.37	
LDL	2.97±1.01	3.03±1.08	2.96±0.98	2.99±0.99	2.91±0.98	2.98±0.96	2.98±1.01	3.04±0.97	2.97±0.94	2.90±0.92	
Diabetes mellitus - no. (%)	1486 (17.0)	355 (16.0)	315 (16.5)	359 (17.4)	457 (17.8)	1108 (12.6)	283 (13.6)	304 (12.3)	303 (12.9)	218 (11.7)	
AFIB/Atrial Flutter - no. (%)	936 (10.7)	301 (13.6)	210 (11.0)	170 (8.23)	255 (9.92)	270 (3.08)	74 (3.57)	69 (2.78)	61 (2.59)	66 (3.55)	
Diuretic Pre-admission - no. (%)	1132 (12.9)	298 (13.5)	260 (13.6)	229 (11.1)	345 (13.4)	782 (8.92)	194 (9.35)	185 (7.46)	204 (8.68)	199 (10.7)	
Diuretic In Hospital - no. (%)	1994 (22.8)	537 (24.3)	418 (21.9)	441 (21.4)	598 (23.3)	352 (12.8)	73 (11.3)	80 (10.2)	95 (13.7)	104 (16.3)	
Current smoker - no. (%)	2623 (29.9)	610 (27.6)	591 (30.9)	666 (32.3)	756 (29.4)	1850 (21.1)	429 (20.7)	522 (21.0)	510 (21.7)	389 (20.9)	

Table 2 – Association of estimated 24-hour sodium excretion quartiles and risk of stroke

	Estimated Sodium Excretion			
	<2.8 g/day (N=4751)	2.8-3.5 g/day (N=4750)	3.5-4.26 g/day (N=4750)	>4.26 g/day (N=4750)
Analysis – odds ratio (95% CI)				
Univariate analysis *	1.40 (1.28-1.52)	1.00	1.15 (1.06-1.25)	1.84 (1.69-2.01)
Multivariate analysis				
Analysis including age and BMI	1.41 (1.29-1.54)	1.00	1.14 (1.05-1.25)	1.86 (1.70-2.03)
Primary analysis †	1.39 (1.26-1.53)	1.00	1.13 (1.03-1.24)	1.81 (1.65-2.00)
Analysis including dietary score and potassium ‡	1.24 (1.12-1.37)	1.00	1.28 (1.16-1.41)	2.49 (2.24-2.77)
Analysis including HTN and medications which modify sodium excretion §	1.16 (1.03-1.30)	1.00	1.22 (1.09-1.36)	2.35 (2.08-2.65)
Sensitivity analysis				
Primary analysis excluding MRC > 2	1.37 (1.18-1.58)	1.00	1.08 (0.95-1.23)	1.64 (1.42-1.88)
Primary analysis excluding urine collection >48 hours	1.28 (1.12-1.47)	1.00	1.18 (1.03-1.34)	1.91 (1.67-2.18)

* The univariate analysis was performed using the logistic regression model.

† The primary model included age, BMI, education level, alcohol, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level.

‡ Dietary score was the alternative healthy eating index (AHEI).

§ Hypertension variables hypertension status, systolic blood pressure and diastolic blood pressure. We adjusted for pre-hospital ace-inhibitor, angiotensin receptor blocker and diuretic use.

Urine collection from time of stroke onset to time of urine collection.

Table 3 – Association of estimated 24-hour potassium excretion quartiles and risk of stroke

	Estimated Potassium Excretion Quartiles			
	Quartile 1 <1.34 g/day (N=4817)	Quartile 2 1.34-1.58 g/day (N=4816)	Quartile 3 1.58-1.86 g/day (N=4817)	Quartile 4 >1.86 g/day (N=4816)
Analysis – odds ratio (95% CI)				
Univariate analysis *	1.00	0.80 (0.73-0.87)	0.67 (0.61-0.73)	0.43 (0.39-0.47)
Multivariate analysis				
Analysis including age and BMI	1.00	0.80 (0.73-0.88)	0.64 (0.59-0.71)	0.42 (0.38-0.46)
Primary analysis †	1.00	0.83 (0.76-0.92)	0.68 (0.62-0.75)	0.46 (0.41-0.51)
Analysis including dietary score and sodium ‡	1.00	0.75 (0.68-0.83)	0.56 (0.51-0.63)	0.33 (0.29-0.37)
Analysis including HTN and medications which modify potassium excretion §	1.00	0.76 (0.68-0.86)	0.57 (0.51-0.65)	0.33 (0.29-0.38)
Sensitivity analysis				
Primary analysis excluding MRC > 2	1.00	0.70 (0.60-0.81)	0.48 (0.41-0.56)	0.24 (0.20-0.28)
Primary analysis excluding urine collection >48 hours	1.00	0.87 (0.76-0.99)	0.78 (0.68-0.89)	0.67 (0.58-0.77)

* The univariate analysis was performed using the logistic regression model.

† The primary model included age, BMI, education level, alcohol, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level.

‡ Dietary score was the alternative healthy eating index (AHEI).

§ Hypertension variables hypertension status, systolic blood pressure and diastolic blood pressure. We adjusted for pre-hospital ace-inhibitor, angiotensin receptor blocker and diuretic use.

Urine collection from time of stroke onset to time of urine collection.


Table 4 – Association of Joint Urinary Sodium and Potassium Excretion with Stroke

Joint Association of Urinary Sodium and Potassium Excretion with Stroke					
	Quartile 1	Quartile 2	Quartile 3	Quartile 4	
	<2.8 g/day	2.8-3.5 g/day	3.5-4.26 g/day	>4.26 g/day	
Potassium less than the median (<1.58 g/day)	OR _{Joint} 2.10 (1.89-2.50) (n=3176)	OR _{Joint} 1.94 (1.69-2.24) (n=2600)	OR _{Joint} 2.62 (2.26-3.05) (n=2217)	OR _{Joint} 4.17 (3.51-4.96) (n=1471)	P for interaction
Potassium greater than or equal to the median (>=1.58 g/day)	OR _{Joint} 1.69 (1.44-1.98) (n=1575)	Ref 1-0 (n=2149)	OR _{Joint} 1.10 (0.95-1.26) (n=2530)	OR _{Joint} 2.26 (1.97-2.59) (n=3278)	<0.001

The primary model included age, BMI, education level, alcohol, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level.

Figures

Figure 1 – Scatterplot of Estimated Urinary Sodium and Potassium Excretion



Accepted Manuscript

Figure 2 – Mean Systolic and Diastolic Blood Pressure by Sodium Quartile
(Controls excluding baseline hypertension and pre-hospital diuretic use)






Figure 3 – Association of estimated 24-hour sodium excretion (Tanaka) with risk of stroke and pathological stroke subtypes



Panel A shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and risk of all stroke. Panel B shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and risk of ischemic stroke. Panel C shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and risk of intracerebral haemorrhage. All plots were adjusted for age, BMI, education level, alcohol intake, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level. The grey ribbons indicate 95% confidence interval. The green lines represents the median value for each population. The distribution of the exposure (sodium excretion) is plotted below each spline.

Figure 4 – Association of estimated sodium excretion (Tanaka) and risk of ischaemic stroke subtypes (TOAST classification)




Panel A shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and cardioembolic stroke (TOAST 1). Panel B shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and large vessel stroke (TOAST 2). Panel C shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and

small vessel stroke (TOAST 3). Panel D shows a restricted cubic spline of the association between estimated 24-hour sodium excretion and stroke of undetermined cause (TOAST 4). All plots were adjusted for age, BMI, education level, alcohol intake, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level. The grey ribbons indicate 95% confidence interval. The distribution of the exposure (potassium excretion) is plotted below each spline.

Accepted Manuscript

Figure 5 – Association of estimated 24-hour potassium excretion (Tanaka) with risk of stroke and pathological stroke subtypes



Panel A shows a restricted cubic spline of the association between estimated 24-hour potassium excretion and risk of all stroke. Panel B shows a restricted cubic spline of the association between estimated 24-hour potassium excretion and risk of ischemic stroke. Panel C shows a restricted cubic spline of the association between estimated 24-hour potassium excretion and risk of intracerebral haemorrhage. All plots were adjusted for age, BMI, education level, alcohol intake, diabetes at baseline, atrial fibrillation/flutter at baseline, smoking and physical activity level. The grey ribbons indicate 95% confidence interval. The green lines represents the median value for each population. The distribution of the exposure (sodium excretion) is plotted below each spline